Atlas Trials

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Clinical trial NCT05670106 · COMPLETED

Trial details

NCT number
NCT05670106
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Start date
2023-05-16
Primary completion
2024-05-17
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.